Biocentury | DTx: Optimizing RNA therapies for cellular uptake, biodistribution

Danielle Golovin

Emerging Company Profile: DTx is slated to enter the clinic next year with its fatty acid ligand conjugated RNA therapy to treat retinitis pigmentosa

Read Full Article